For many years, moderate alcohol intake and its effect on health have been subject to much debate, particularly concerning cardiovascular health. Indeed, light-to-moderate use of alcohol has been ...

MALVERN, Pa., March 25, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), a leading remote medical technology company focused on the delivery of health information to improve quality of life ...

CredibleMeds, a valuable resource for prescribing physicians, now includes information from FDA drug labels to inform prescribers of any ECG monitoring recommendations, warnings for use in congenital ...

Long QT syndrome is a leading cause of sudden death in young persons, with a prevalence exceeding 1 in 2000. It is characterized by prolongation of the QT interval, aberrant T-wave morphologic ...

Please provide your email address to receive an email when new articles are posted on . More than 13% of users of quetiapine and haloperidol developed severe QT prolongation. Severe QT prolongation ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. A new analysis from Michigan's largest health system provides sobering verification of the risks ...

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives discussed upcoming clinical readouts and pipeline priorities during the ...

Romano-Ward syndrome, the most common congenital long QT disorder, often causes exertion- or stimulus-triggered syncope and sudden death; genetic testing and beta blockers guide prevention.

As more consumer-facing devices add features to measure the heart’s electrical activity, companies are looking for new ways to turn this data into valuable health information. AliveCor, a startup that ...

(HealthDay News) — Use of a computerized clinical decision support system (CDSS) may reduce the risk of prolonged QT c interval in hospitalized patients at risk for torsades de pointes, according to ...

Researchers have been using artificial intelligence (AI) to develop a mobile device that can identify certain patients at risk of sudden cardiac death. Researchers from Mayo Clinic and AliveCor Inc.